Table 3.

Individual patient characteristics

Patient No.FGFR fusionAge, ySexStageHistologyAdjuvant therapyRFS (mo)OS (mo)
1FGFR3-TACC3*48MII BSCCUnknownUnknownUnknown
2FGFR3-TACC3Δ70MI BSCCGemcitabine + cisplatin4.6+4.6+
3FGFR3-TACC3Δ49MIII ASCCUnknown11.418.4
4FGFR3-TACC3°55MIII ASCCTarceva13.014.0+
5FGFR3-TACC355MII aSCCPemetrexed + carboplatin37.0+37.0+
6FGFR3-TACC3*65MI BSCCRadiotherapy6.010.5
7FGFR3-TACC362MII BSCCUnknown2.02.0+
8FGFR3-TACC362MII BSCCUnknown26.0+26.0+
9FGFR3-TACC3Δ46MI aSCCUnknown18.0+18.0+
10FGFR3-TACC3Δ75MII AADNavebine + cisplatin20.3+33.8+
11FGFR3-TACC3Δ64MIII AADPemetrexed + cisplatin32.2+32.2+
12FGFR3-TACC3Δ56MI BADGemcitabine + cisplatin10.729.1
13FGFR3-TACC3Δ52MI BADGemcitabine + cisplatin25.8+27.3+
14FGFR3-TACC3Δ62MII AADPemetrexed + cisplatin12.013.5
15FGFR3-TACC3Δ45FIII AADPemetrexed + cisplatin19.527.0+
16BAG4-FGFR161MII BSCCNavebine + cisplatin22.5+45.0+
17BAG4-FGFR148MI BSCCGemcitabine + cisplatin16.0+16.0+

Abbreviation: AD, adenocarcinoma.

FGFR3-TACC3*, FGFR3-TACC3 (E18:E11 INS78 bp intron from TACC3).

FGFR3-TACC3Δ, FGFR3-TACC3 (E17:E11).

FGFR3-TACC3°, FGFR3-TACC3 (E17:E8).

FGFR3-TACC3♀, FGFR3-TACC3 (E17:E5 INS71 bp intron from TACC3).

FGFR3-TACC3♂, FGFR3-TACC3 (E17:E10).

BAG4-FGFR1, BAG4-FGFR1 (E1:E8).